In the BioHarmony Drug Report Database
Ventavis (iloprost) is a small molecule pharmaceutical. Iloprost was first approved as Ventavis on 2003-09-15. It is used to treat pulmonary hypertension in the USA. It has been approved in Europe to treat pulmonary hypertension. The pharmaceutical is active against prostacyclin receptor. In addition, it is known to target prostaglandin E2 receptor EP4 subtype, prostaglandin E2 receptor EP2 subtype, prostaglandin E2 receptor EP3 subtype, prostaglandin D2 receptor, thromboxane A2 receptor, prostaglandin F2-alpha receptor, and prostaglandin E2 receptor EP1 subtype.
Image (chem structure or protein)